Furthermore, the activation of PD-L1/PD-L2 expressing CD163+TAMs “resets” CD3-CD56hiCD16-ve NK cell activation that mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in Hodgkin lymphoma (CHL) and diffuse large B-cell Lymphoma (DLBCL) with doxorubicin (DOX)-based therapy [44]. Here, CD163 is linked to diffuse large B-cell lymphoma.